Tag: Cardiac myosin inhibitors

Hypertrophic cardiomyopathy (HCM) affects an estimated 1 in 500 people, though some genetic data suggests the prevalence could be as high as 1 in 200 [1.5.4, 1.8.5]. Historically, treatments only managed symptoms. So, *what is the new medication for hypertrophic cardiomyopathy* that offers a targeted approach?

While no specific drug is marketed as a 'myosin tablet,' the term often refers to muscle relaxants like Myosone, which contains the active ingredient eperisone. Myosin is actually a protein essential for muscle contraction, but several medications target the myosin family for various therapeutic effects.